CBD shows promise in animal models of autism—but key gaps remain
Behavioral pharmacology of isolated cannabidiol in animal models of autism spectrum disorder: a systematic review.
AI Summary
This systematic review examined isolated cannabidiol (CBD) in animal models designed to reflect features of autism spectrum disorder (ASD). Across nine eligible studies—mostly in rodents, with some zebrafish research—CBD was associated with improvements in repetitive behavior, social interaction, recognition memory, and excessive movement. Effects varied depending on the dose, animal model, and treatment schedule, while anxiety-related benefits were inconsistent. The abstract does not report pooled effect sizes or percentages.
The behavioral changes were accompanied by alterations in markers such as CB1 receptors, parvalbumin-containing interneurons, oxidative and nitrosative stress, and brain-cell or neuroanatomical features linked to ASD-related behavior. However, the findings are promising but heterogeneous, and important limitations include limited analysis of sex differences and incomplete reporting of methods used to reduce bias. For cannabis users and families, the main practical message is that these results do not establish CBD as an ASD treatment in people; more rigorous studies are needed to clarify dosing, safety, long-term effects, mechanisms, and relevance to humans.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
CBD was linked to stronger beta-band brain connectivity in a small EEG subset
Mouse study links CBD’s anxiety-like effects to LHb α3 glycine receptors
Animal and cell study links CBD-rich extract with fewer UVB tumours
Explore More Research
Stay informed about the latest cannabis science.